- Business22 September 2022
Adalvo is delighted to announce the successful DCP approval of our Teriflunomide 14 mg film-coated divisible tablets.
- Business20 September 2022
Adalvo is pleased to announce the addition of Fidaxomicin Film Coated Tablets, to our Product Portfolio within the antibiotic line. Our product is being developed in collaboration with one...
- Business15 September 2022
One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are pleased to...
- Business13 September 2022
Adalvo is pleased to announce the addition of Brivaracetam film coated tablets, to our product Portfolio. We are currently working on dossier completion for this product, which is expected in...
- Business09 September 2022
Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem...
- Business02 September 2022
The core strategy of Adalvo’s portfolio is innovation and differentiation, which allows us to make unique products available in the market, and supports our partners to target unmet medical needs....
- Business30 August 2022
August commemorates Psoriasis Awareness month and is used as an opportunity to educate and inform on a range of topics varying from treatment, causes, triggers and management of the inflammatory...
- Business25 August 2022
Adalvo and Hikma Sign Exclusive Licensing Agreement to Commercialise a product in the Allergic Rhinitis space across MENA Markets
Adalvo is pleased to announce that we have signed an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, to commercialise a nasal spray indicated in the treatment...
- Business23 August 2022
We at Adalvo continue to strengthen our comprehensive pain management portfolio, covering a unique selection of products conducive to this indication.
- Business19 August 2022
Adalvo is very proud to announce that our dossier for Pregabalin ER tablets has been submitted successfully. Pregabalin is a backbone medication indicated in the treatment of Neuropathic pain.
- Business12 August 2022
We are pleased to announce that our dossier submission for Eribulin solution for injection, 0.44mg/ml has been completed.
- Business09 August 2022
Adalvo is pleased to announce our successful DCP closure for Fulvestrant pre-filled injection. Our product is a fully EU compliant generic version of Faslodex, which is a widely used drug,...
- Business02 August 2022
Adalvo is thrilled to announce the acquisition of our first branded product, Onsolis® after concluding a deal with a reputable US based specialty pharmaceutical Company, who originally owned the product....
- Business28 July 2022
We are pleased to announce that we have now completed our Pilot BE program for Palbociclib Film-coated Tablets, which is being developed in collaboration with our oncology specialty, sister company, forming...
- Business15 July 2022
Adalvo is delighted to announce the successful DCP closure of our Dimethyl Fumarate 120mg, 240mg hard capsules in Europe.
- Business04 July 2022
Adalvo is very proud to announce that our Phase III Study for Pregabalin ER tablets has been completed successfully. The study was conducted with a patient population of over 450...
- Business23 June 2022
Adalvo is now able to offer over 100 tailor-made products to our partners. As part of our growth journey, our focus has always been to bring high-value, differentiated products, covering...
- Business21 June 2022
We are pleased to announce that we have now completed our Pivotal BE program for Tafamidis Meglumine Soft Gel Capsules 20mg.
- Business16 June 2022
Adalvo is pleased to announce that our dossier for Apremilast Film-Coated Tablets is complete and our DCP submission is scheduled for January 2023.